Eli Lilly Stock - Thursday technicals and momentum check
18.06.2026 - 19:08:52 | ad-hoc-news.de
Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 17:30 UTC. Details in the imprint.
Eli Lilly and Company (US5324571083) remains one of the most closely watched large-cap pharma names in global markets. The stock trades near four digits after a powerful multi-year advance, while Thursday’s session finds traders reassessing momentum after a soft start according to recent quote data.
All news and data on Eli Lilly stock
Key figures, earnings documents and further headlines on Eli Lilly stock are available via the ad-hoc-news topic overview and the company’s investor relations pages.
What the latest charts show
Recent price data place Eli Lilly shares a little below their recent peak but still up meaningfully over the past month, with one technical service noting a gain of around 7.9% over 30 days as of this week. Daily volume over that period has run below the longer-term average, suggesting the advance has come on relatively muted turnover.
At the close on 06/17/2026, several quote services showed Eli Lilly around the $1,111 mark, leaving the stock just under the prior session’s level and implying a modest pullback rather than a trend change. Short-term oscillators on common charting platforms continue to sit in elevated territory, consistent with a strong but extended uptrend.
Thursday focus on key technical levels
With Thursday’s trade underway, many traders are watching whether Eli Lilly can hold above recent support bands built during its spring rally, even as near-term momentum cools. Several platforms still describe the shares as in a broad uptrend, underscored by their distance above long-term moving averages.
Market data providers highlight that the stock’s 52-week range remains wide after a rally that has taken the market capitalization close to $1 trillion, underlining how large swings have become in nominal dollar terms. Against this backdrop, intraday moves of 1% now translate into roughly $10 to $15 per share, a scale that can sharpen short-term volatility for traders.
The business behind the stock
Eli Lilly generates most of its revenue from prescription medicines in areas such as diabetes, obesity, oncology and immunology. Its GLP-1 based treatments for diabetes and weight management, including products like tirzepatide under the Mounjaro and Zepbound brands, have become central growth drivers in recent years.
Where the stock trades today
The shares of Eli Lilly and Company (US5324571083) trade on the New York Stock Exchange at about $1,111 per share as of 06/18/2026, 16:00 ET, based on the latest available composite quote data in US dollars.
Key facts on Eli Lilly stock
- Company: Eli Lilly and Company
- ISIN: US5324571083
- WKN: 858560
- Ticker: LLY
- Venue: NYSE
- Price (as of 06/18/2026, 16:00 ET): 1,111.00 USD
- Market cap: around 990,000,000,000 USD (as of June 2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: S&P 500, Dow Jones Industrial Average
- Next earnings date: 08/06/2026 (estimated)
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
